Losing ESCR Money

Really. You know the song, Promises, Promises?

It is “promising but controversial research,” says the Wall Street Journal. It is a “promising new science,” Time magazine agrees. Scientists “hope to be able to use” ESCR to treat many diseases, Reuters reports. The Los Angeles Times cites a White House spokesman who said judge’s decision “carries the potential to block ‘critical, life-saving research.’"

You could say that ESCR is the “most promising” line of research, in the sense that the researchers involved have definitely been doing the most promising. They’ve been promising great things, and to date delivering nothing.

Yup.